Study guide
16.3 STIs in Pregnancy, Neonates & Children, Contraception, Sexual Health & Psychosexual Problems
UEMS European Board of Dermatovenereology Diploma Examination Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Structure, Eligibility & Examination Regulations
1.1 EBDVD Exam Format, Session Timing & Scoring Rules 1.2 Eligibility Routes, Application Requirements & Re-take Regulations 1.3 UEMS-EBDV Governance, European Training Requirements & Diploma Recognition
2 Chapter 2: Dermatologic Terminology, Lesion Morphology & Skin Biology
2.1 Skin Anatomy, Epidermal Biology & Barrier Function 2.2 Primary & Secondary Lesion Morphology 2.3 Cutaneous Immunology & Pathophysiological Reaction Patterns
3 Chapter 3: Dermatopathology & Diagnostic Procedures
3.1 Biopsy Selection, Processing & Special Staining Techniques 3.2 Major Histopathologic Patterns & Tissue Reaction Types 3.3 Direct & Indirect Immunofluorescence Microscopy
4 Chapter 4: Epidemiology, Photobiology & Occupational Dermatology
4.1 Epidemiological Principles & Cutaneous Disease Burden 4.2 Photobiology & Photoprotection 4.3 Occupational Dermatoses & Contact Sensitisation Surveillance
5 Chapter 5: Papulosquamous, Follicular & Adnexal Disease
5.1 Psoriasis: Variants, Psoriatic Arthritis, Comorbidity & European Management 5.2 Lichen Planus, Lichenoid Eruptions & Other Papulosquamous Disorders 5.3 Acne Vulgaris, Rosacea & Perioral Dermatitis 5.4 Hidradenitis Suppurativa, Hyperhidrosis & Other Sweat Gland Disorders
6 Chapter 6: Hair, Nails & Pigmentary Disorders
6.1 Hair Disorders: Non-Scarring & Scarring Alopecia, Hair Shaft Defects & Hirsutism 6.2 Nail Disorders, Onychomycosis & Nail Unit Tumours 6.3 Pigmentary Disorders: Vitiligo, Melasma & Other Hypo- and Hyperpigmentation
7 Chapter 7: Drug Reactions, Granulomatous & Deposition Disease and Skin Signs of Systemic Disease
7.1 Cutaneous Adverse Drug Reactions, SCARs & Dermatological Emergencies 7.2 Granulomatous & Deposition Disorders and Panniculitis 7.3 Skin Signs of Systemic Disease, Porphyrias, Nutritional Deficiency & Paraneoplastic Dermatoses
8 Chapter 8: Pruritus, Pregnancy & Geriatric Dermatology, Physical Injury and Mucosal Disease
8.1 Chronic Pruritus, Chronic Prurigo, Dermatoses of Pregnancy & Geriatric Dermatology 8.2 Burns, Cold, Heat & Radiation Injury and the Principles of Wound Healing 8.3 Oral Mucosal, Lip, Genital Mucosal & Perianal (Proctological) Disease
9 Chapter 9: Autoimmune Bullous Diseases
9.1 Pemphigus Group: Pemphigus Vulgaris, Foliaceus & Paraneoplastic Pemphigus 9.2 Pemphigoid Group & Epidermolysis Bullosa Acquisita 9.3 Dermatitis Herpetiformis & Linear IgA Bullous Dermatosis
10 Chapter 10: Eczematous Disorders, Urticaria & Allergology
10.1 Atopic Dermatitis: Pathogenesis, Phenotypes & European Management 10.2 Allergic & Irritant Contact Dermatitis: Pathogenesis, Investigation & Common Allergens 10.3 Urticaria, Angioedema & Cutaneous Mastocytosis 10.4 Immediate-Type Allergy: Diagnostics, Anaphylaxis, Food, Venom & Drug Allergy
11 Chapter 11: Connective Tissue Diseases & Cutaneous Vasculitis
11.1 Cutaneous Lupus Erythematosus Spectrum & Systemic Manifestations 11.2 Dermatomyositis, Systemic Sclerosis & Scleroderma Spectrum 11.3 Cutaneous Vasculitis & Neutrophilic Dermatoses
12 Chapter 12: Paediatric & Genetic Dermatology
12.1 Vascular Anomalies & Benign Neonatal Dermatoses 12.2 Hereditary Ichthyoses & Disorders of Keratinisation 12.3 Genodermatoses, Neurocutaneous Syndromes & Epidermolysis Bullosa
13 Chapter 13: Bacterial, Mycobacterial, Parasitic & Zoonotic Cutaneous Infections
13.1 Bacterial Skin & Soft Tissue Infections 13.2 Mycobacterial Infections: Cutaneous Tuberculosis, Leprosy & Atypical Mycobacteria 13.3 Parasitic Infestations, Arthropod Bites & Cutaneous Leishmaniasis 13.4 Lyme Borreliosis, Rickettsioses & Other Zoonotic and Travel-Related Skin Infections
14 Chapter 14: Viral & Fungal Cutaneous Infections
14.1 Herpesviridae Infections: HSV, VZV & HHV-8 14.2 Poxviruses & Human Papillomavirus Manifestations 14.3 Superficial, Subcutaneous & Deep Mycoses
15 Chapter 15: Sexually Transmitted Infections & Genital Infections
15.1 Syphilis: Pathogenesis, Clinical Stages, Serology & European Management 15.2 Neisseria gonorrhoeae, Chlamydia trachomatis & Genital Ulcer Diseases 15.3 HIV-Related Dermatoses, Partner Notification & Anogenital Lichen Sclerosus 15.4 Non-Gonococcal Urethritis, Mycoplasma genitalium, Trichomoniasis, Vaginal Infections & Balanitis
16 Chapter 16: Sexual Health Services, HIV Prevention & Anogenital Medicine
16.1 STI Epidemiology, Prevention, Services, Sexual History, HIV Testing, ART & PrEP/PEP 16.2 HPV-Related Anogenital Neoplasia, Cervical Screening & Common Gynaecological and Andrological Disorders 16.3 STIs in Pregnancy, Neonates & Children, Contraception, Sexual Health & Psychosexual Problems
17 Chapter 17: Keratinocyte Carcinomas, Precancerous Lesions & Other Skin Tumours
17.1 Actinic Keratoses, Bowen Disease & Field Cancerisation 17.2 Basal Cell Carcinoma: Subtypes, Risk Stratification & Management 17.3 Cutaneous Squamous Cell Carcinoma & Keratoacanthoma 17.4 Benign & Malignant Epidermal, Adnexal, Mesenchymal and Vascular Tumours, Cysts, Histiocytoses & Metastases
18 Chapter 18: Melanocytic Naevi & Melanoma
18.1 Benign Melanocytic Naevi: Acquired, Congenital, Spitz, Blue, Halo & Atypical Naevi 18.2 Melanoma Risk Factors, Clinical Presentation & Biopsy Protocol 18.3 Melanoma Histopathology, Breslow Thickness & Staging 18.4 Systemic Therapy for Advanced & Metastatic Melanoma
19 Chapter 19: Dermoscopy, Skin Imaging & Cutaneous Lymphomas
19.1 Dermoscopic Principles, Structures & Algorithmic Approaches 19.2 Dermoscopy of Non-Melanocytic Cutaneous Neoplasms 19.3 Non-Invasive Skin Imaging, Skin Function Measurement, Teledermatology & Skin Cancer Surveillance 19.4 Cutaneous Lymphomas, Merkel Cell Carcinoma & Cutaneous Sarcomas
20 Chapter 20: Dermatopharmacology, Systemic Therapeutics & Prescribing
20.1 Topical Corticosteroids, Calcineurin Inhibitors & Retinoids 20.2 Systemic Immunosuppressive & Biologic Therapies 20.3 Oral Retinoids & Phototherapy Modalities 20.4 Dermatological Prescribing: Anti-Infectives, Antihistamines, Antimalarials, Dapsone, Special Populations & Cutaneous Toxicity of Cancer Therapy
21 Chapter 21: Dermatosurgery, Cryotherapy, Lasers & Aesthetic Procedures
21.1 Surgical Anatomy, Local Anaesthesia & Excision Principles 21.2 Cutaneous Reconstructive Flaps, Skin Grafts & Surgical Complications 21.3 Cryosurgery, Electrosurgery & Cutaneous Lasers 21.4 Aesthetic & Corrective Dermatology, Photodynamic Therapy & Dermatological Radiotherapy
22 Chapter 22: Phlebology, Angiology, Psychodermatology & EBDVD Revision
22.1 Phlebology, Chronic Venous Insufficiency & Lower Extremity Ulcers 22.2 Angiology: Arterial Disease, Raynaud Phenomenon, Livedo, Thrombosis, Lymphoedema & Lipoedema 22.3 Psychodermatology, Delusional Infestation & Factitious Disorders 22.4 EBDVD Revision Strategy & Cross-Topic Review
16.3 STIs in Pregnancy, Neonates & Children, Contraception, Sexual Health & Psychosexual Problems
Key Takeaways Explain This Topic AI
Antenatal screening for syphilis, HIV, and hepatitis B is recommended for all pregnant women in Europe because effective treatment prevents most vertical transmission.
A first episode of genital herpes in the third trimester, especially within 6 weeks of delivery, carries the highest neonatal herpes risk, and caesarean section is recommended.
Gonococcal ophthalmia neonatorum usually appears 2 to 5 days after birth and chlamydial conjunctivitis 5 to 14 days after birth.
Gonorrhoea, syphilis, chlamydia, or trichomoniasis beyond the neonatal period in a prepubertal child strongly suggests sexual abuse and needs referral to child safeguarding services.
A copper intrauterine device inserted within 5 days of unprotected sex is the most effective emergency contraception; ulipristal acetate works up to 120 hours and levonorgestrel up to 72 hours.
Last updated: September 2026
- 16.3 STIs in Pregnancy, Neonates & Children, Contraception, Sexual Health & Psychosexual Problems
- Antenatal Screening
European antenatal programmes offer every pregnant woman testing for syphilis, HIV, and hepatitis B early in pregnancy, because treatment prevents most transmission to the baby. Some countries also screen for chlamydia in younger women, and repeat syphilis and HIV testing in the third trimester for women at ongoing risk.
Specific Infections in Pregnancy
Infection Risk to the Baby Management in Pregnancy
Syphilis Transmission at any stage, highest in early (primary and secondary) syphilis; miscarriage, stillbirth, prematurity, congenital syphilis Benzathine penicillin G by stage; desensitise if allergic (see the syphilis section). Monitor for a Jarisch-Herxheimer reaction , which can cause contractions and fetal distress. Evaluate the newborn
HIV Transmission in utero, at delivery, and through breastfeeding ART for all pregnant women , continued lifelong. With a viral load below 50 copies/mL near term (around 36 weeks), vaginal delivery is usually planned. The newborn receives antiretroviral prophylaxis. With suppressed viral load, transmission is well below 1%
Hepatitis B Perinatal transmission, often leading to chronic infection Test HBsAg. With a high maternal viral load , give tenofovir in the third trimester. The baby receives hepatitis B vaccine and immunoglobulin soon after birth (ideally within 12–24 hours)
Genital herpes (HSV) Neonatal herpes : skin, eye, and mouth disease; encephalitis; or disseminated disease See below
Gonorrhoea and chlamydia Ophthalmia neonatorum ; chlamydial pneumonia at 1–3 months; preterm birth Gonorrhoea: ceftriaxone. Chlamydia: azithromycin or amoxicillin, because doxycycline is contraindicated in pregnancy. Test of cure in pregnancy
Trichomoniasis and bacterial vaginosis Preterm birth and low birth weight Metronidazole is safe; treat symptomatic women
Anogenital warts Rarely, juvenile recurrent respiratory papillomatosis (HPV 6 and 11) Warts often grow in pregnancy. Use cryotherapy or trichloroacetic acid ; avoid podophyllotoxin and 5-fluorouracil. Caesarean section is not needed for warts alone unless they block the birth canal
Genital Herpes in Pregnancy
Highest risk: a first episode (primary infection) in the third trimester , especially within 6 weeks of delivery, because the mother has not yet made protective antibodies. Caesarean section is recommended in this situation.
Recurrent herpes carries a low neonatal risk (maternal antibodies protect the baby). Vaginal delivery is usually appropriate, and suppressive aciclovir or valaciclovir from 36 weeks reduces lesions at term.
A first episode earlier in pregnancy is treated with aciclovir, followed by suppression from 36 weeks.
Neonatal herpes presents in the first weeks of life with vesicles, eye or mouth lesions, lethargy, seizures, or sepsis. It needs urgent IV aciclovir .
Neonatal Infection
Condition Typical Onset Management
Gonococcal ophthalmia neonatorum 2–5 days after birth; copious purulent discharge, risk of corneal perforation Single dose of ceftriaxone (25–50 mg/kg, maximum 125 mg); treat the mother and her partner
Chlamydial conjunctivitis 5–14 days after birth; watery then purulent discharge Oral macrolide (azithromycin or erythromycin; erythromycin carries a small risk of pyloric stenosis)
Chlamydial pneumonia 1–3 months; afebrile, staccato cough Oral macrolide
Early congenital syphilis Up to 2 years: snuffles, rash including palms and soles, bullous lesions, hepatosplenomegaly Aqueous penicillin; see the syphilis section
- Neonatal herpes First 1–4 weeks IV aciclovir
- Children with Genital Infections
The syllabus asks for multidisciplinary management . An STI in a child can come from the mother at birth, from non-sexual contact, or from sexual abuse . Each finding must be interpreted carefully, with a paediatrician and the local child safeguarding team .
Finding in a Prepubertal Child (beyond the neonatal period) Interpretation
Gonorrhoea, syphilis (not congenital), chlamydia (beyond about the first 2–3 years), trichomoniasis Strongly suggests sexual abuse ; refer to safeguarding
Anogenital warts May be vertical (especially in infants), from caregivers' hand warts, or from autoinoculation, but abuse must be considered , particularly as the child gets older
- Genital herpes Possible abuse; also autoinoculation from oral herpes
- HIV Usually vertical; consider abuse if the mother is negative
Mimics of abuse: lichen sclerosus (purpura and fissures in girls), perianal streptococcal dermatitis , threadworm, labial adhesions, Crohn disease, and accidental injury.
Forensic standards: use validated tests (for gonorrhoea and chlamydia, culture or a NAAT confirmed with a second target), keep documentation and chain of custody, and involve trained staff.
Adolescents: follow local laws on consent and confidentiality, assess competence, and screen for exploitation and coercion.
Methods of Contraception
Method Typical Effectiveness Points for Dermatology
Implant, levonorgestrel IUS, copper IUD (long-acting reversible contraception) Most effective, below 1% failure a year Suitable when highly effective contraception is needed with teratogenic drugs (isotretinoin, acitretin, methotrexate, mycophenolate, thalidomide)
Injectable progestogen Effective with timely injections Bone density loss with long-term use
Combined hormonal (pill, patch, ring) Effective with correct use Can improve acne and hirsutism (antiandrogenic progestogens). Raises venous thromboembolism risk. Avoid in migraine with aura, smokers over 35, and antiphospholipid antibodies/lupus with thrombosis risk . Oestrogens can worsen melasma, hereditary angioedema, and porphyria cutanea tarda
- Progestogen-only pill Effective with strict timing An alternative when oestrogen is contraindicated
- Condoms Less effective alone for pregnancy The only method that also protects against STIs
Drug interactions: enzyme inducers reduce hormonal contraception. Dermatology examples include rifampicin (hidradenitis and leprosy regimens), griseofulvin , carbamazepine, St John's wort, and some antiretrovirals. Use an IUD or add another method.
Emergency contraception:
A copper IUD within 5 days of unprotected sex is the most effective option.
Ulipristal acetate 30 mg works up to 120 hours .
Levonorgestrel 1.5 mg works up to 72 hours (less well with higher body weight; double dose with enzyme inducers).
Sexual Health and Psychosexual Problems
The WHO defines sexual health as a state of physical, emotional, mental, and social well-being related to sexuality, not merely the absence of disease. Good venereology care includes sex education, prevention, and attention to sexual function.
Erectile dysfunction: often vascular and an early marker of cardiovascular disease and diabetes. PDE5 inhibitors (sildenafil, tadalafil) are contraindicated with nitrates .
Other male problems: premature ejaculation and low desire.
Female problems: low desire, arousal disorders, dyspareunia , vaginismus , and vulvodynia.
Impact of skin disease: genital psoriasis, lichen sclerosus, hidradenitis suppurativa, and chronic eczema commonly impair sexual function and should be asked about.
Anxiety about STIs: some patients have persistent fear of infection despite negative tests ( "venereophobia" ), which may need psychological support.
Referral: to psychosexual medicine, psychology, gynaecology, or urology as needed.
Gender-affirming care: testosterone often causes acne and androgenetic hair loss; oestrogen and antiandrogens reduce body hair.